Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Shaoxing Zhu"'
Publikováno v:
Journal of Clinical Oncology. 38:TPS588-TPS588
TPS588 Background: Platinum-based chemotherapy is standard first-line treatment for patients with advanced urothelial carcinoma (UC). Checkpoint inhibitors (ie, anti-PD-1 antibodies) are first-line treatment options for cisplatin-ineligible patients.
Autor:
Hong Luo, Chaohong He, Chuanjun Du, Xiaojian Qin, Shaoxing Zhu, Zhongquan Sun, Weiqing Han, Qing Zou, Weijie Gu, Tie Chong, Ben Wan, Dingwei Ye, Xin Yao
Publikováno v:
Journal of Clinical Oncology. 38:90-90
90 Background: SHR3680 is a novel and pure androgen-receptor (AR) antagonist that shows a potent antitumor activity against CRPC but with much less brain distribution than enzalutamide in preclinical study. In this first-in-human phase 1/2 study, the